Bausch Health Enhances Liver Disease Solutions with DURECT Acquisition Bausch Health's recent acquisition of DURECT Corporation aims to bolster its liver disease treatment portfolio, focusing on innovative therapies.

Bausch Health Enhances Liver Disease Solutions with DURECT Acquisition #Canada #Larsucosterol #DURECT_Corporation #Laval #Bausch_Health

DURECT Corporation Achieves Key Milestones in Q1 2025 Financial Report and Business Updates DURECT Corporation shares its Q1 2025 financial results and insights on business strategies, focusing on larsucosterol's Phase 3 trial for alcohol-associated hepatitis.

DURECT Corporation Achieves Key Milestones in Q1 2025 Financial Report and Business Updates #USA #Cupertino #Larsucosterol #DURECT_Corporation #alcohol-associated_hepatitis

DURECT Corporation Reveals 2024 Financial Performance and Strategic Developments DURECT Corporation shares its financial results for the fourth quarter and full year 2024, highlighting advancements in larsucosterol development.

DURECT Corporation Reveals 2024 Financial Performance and Strategic Developments #United_States #Cupertino #Larsucosterol #AHFIRM_Trial #DURECT_Corporation

DURECT Corporation Announces Publication of Larsucosterol Phase 2b Results in NEJM Evidence | DURECT Jan 28, 2025, 10:09 ET The article presents new trial data, including subgroup analyses and liver biomarkers, which have guided the design of the Company&#0 ...

As a steroid nihilist, I’m happy to read this.
My interpretation of the AHFIRM data is that #larsucosterol works for severe alcohol associated hepatitis. I don’t love the primary endpoint but hey…I will take 30-50% 90 day mortality ⬇️ any day.
This is literally all i see on service.
#liversky

DURECT Corporation to Present Breakthrough Epigenetic Therapies at Major Healthcare Conference Discover DURECT Corporation's plans to present its innovative epigenetic therapies at the upcoming Oppenheimer 35th Annual Healthcare Conference. Learn more about the company's advancements.

DURECT Corporation to Present Breakthrough Epigenetic Therapies at Major Healthcare Conference #United_States #Cupertino #Healthcare_Conference #Larsucosterol #DURECT_Corporation

DURECT Corporation Publishes Promising Larsucosterol Findings for Alcohol-Associated Hepatitis DURECT Corporation has published significant Phase 2b trial data on Larsucosterol, showing promising results for treating Alcohol-Associated Hepatitis.

DURECT Corporation Publishes Promising Larsucosterol Findings for Alcohol-Associated Hepatitis #USA #DURECT #Cupertino #Larsucosterol #AHFIRM_Trial

#larsucosterol @DURECTCorp doesn’t meet the primary endpoint of win probability globally (but does in US)
More importantly, reduction in mortality at 90 days quite impressive and 20% fewer SAEs (much better than anything we have)
Ph3 study planned
#easlcongress #livertwitter